Clinical Trial Update: Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update indicates a Phase 2 neoadjuvant study of Darsilide combined with an aromatase inhibitor, trastuzumab, and Patuzumab for HR+/HER2+ bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Darsilide
• Patuzumab (Patuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING